Pharma Moves In: Investors, Developers and Lilly’s Carole Ho Discuss Psychedelic Drug Development at Healthcare Forum

Investors and drug developers at the Psychedelic Healthcare Forum described a shifting landscape for psychedelic medicine, with efficacy, regulatory clarity, and intellectual property concerns seen as less daunting than they were several years ago. Speakers said reimbursement, REMS requirements, and operational execution remain major unresolved risks. They also discussed how large pharmaceutical companies can provide capital, infrastructure, and the ability to test treatments across broader indications, while biotechs remain more focused because of funding limits. Potential opportunities highlighted included PTSD, depressive disorders, and niche indications. The forum also examined renewed interest in neuroscience among major pharmaceutical companies and the importance of novel formulations and prodrugs in attracting industry investment. Lilly’s Carole Ho is identified in the headline as discussing 5-MeO-DMT in relation to the Spravato model, although the supplied excerpt provides no further detail on that conversation.